As we approach the end of the year, it’s time to take stock of the exciting landscape of pre-seed, seed and Series A funding in Europe and beyond. With a constant stream of innovations driving the biotech industry, what are the investment opportunities to watch for in 2024? Which models, therapeutic areas or innovative technologies are currently capturing the spotlight? What are investors’ expectations regarding project maturity? How can early-stage biotech companies position themselves to be highly attractive for investment? Could we see a rise in pre-seed and seed money for 2024?
Moderator: Alexander Sinclair-Wilson, Associate Director of Investments, Sanofi Ventures 
